A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-14

Study Completion Date

2025-02-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is the first study in the RestorAATion clinical program.

The purpose of this first-in human (FIH), double-blind, randomized, placebo-controlled, single ascending dose (SAD) and multiple-dose Phase 1 study is to assess the safety, tolerability, and PK of WVE-006 compared to placebo in healthy participants following a single dose (Period 1) and multiple doses (Period 2) of WVE-006.

This information will be used to determine doses and regimes that have the potential to be pharmacologically active in patients with Alpha-1 antitrypsin deficiency in the RestorAATion 2 study, and the maximum safe and tolerable dose that may be given to these patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

NCT04167345

Alpha 1-Antitrypsin Deficiency

TERMINATED PHASE2

A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype

NCT05643495

Alpha-1 Antitrypsin Deficiency

TERMINATED PHASE2

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

NCT04474197

Alpha1-Antitrypsin Deficiency

COMPLETED PHASE2

Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

NCT02168686

Alpha 1-Antitrypsin Deficiency

COMPLETED PHASE1/PHASE2

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

NCT03945292

Alpha 1-Antitrypsin Deficiency

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alpha-1 Antitrypsin Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental WVE-006 (Dose A) or placebo

Group Type EXPERIMENTAL

WVE-006

Intervention Type DRUG

RNA editing oligonucleotide

Experimental WVE-006 (Dose B) or placebo

Group Type EXPERIMENTAL

WVE-006

Intervention Type DRUG

RNA editing oligonucleotide

Experimental WVE-006 (Dose C) or placebo

Group Type EXPERIMENTAL

WVE-006

Intervention Type DRUG

RNA editing oligonucleotide

Experimental WVE-006 (Dose D) or placebo

Group Type EXPERIMENTAL

WVE-006

Intervention Type DRUG

RNA editing oligonucleotide

Experimental WVE-006 (Dose E) or placebo

Group Type EXPERIMENTAL

WVE-006

Intervention Type DRUG

RNA editing oligonucleotide

Experimental WVE-006 (Dose F) or placebo

Group Type EXPERIMENTAL

WVE-006

Intervention Type DRUG

RNA editing oligonucleotide

Experimental WVE-006 (Dose G) or placebo

Group Type EXPERIMENTAL

WVE-006

Intervention Type DRUG

RNA editing oligonucleotide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

WVE-006

RNA editing oligonucleotide

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy as determined by the Investigator, based on a medical evaluation.
* Genetic testing confirming PI\*MM.
* Participant has been a non-smoker for at least 1 year prior to screening.

Exclusion Criteria

* Participant has a history of multiple drug allergies or of allergic reaction to an oligonucleotide or to N-acetylgalactosamine (GalNAc).
* Participant has a history of intolerance or any medical condition that might interfere with subcutaneous injections.
* Any ongoing or recent infections.
* Any recent or planned vaccinations during the study.
* Participant has a history of regular alcohol consumption exceeding 14 standard drinks/week.
* Unwilling to abstain from alcohol for 48 hours prior to dosing at each of the dosing visits.
* Participant has a history of caffeine consumption exceeding 8 cups of coffee/day.
* Use of prescription or non-prescription medications, including vitamin, dietary, and herbal supplements (including St John's Wort) within 7 days prior to the first dose of study treatment unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with interpretation of study assessments. Contraception and hormone replacement therapy (HRT) are permitted. If needed, over-the-counter (OTC) medications such as paracetamol/acetaminophen may be used acutely.
* Any recent or planned major surgery during the study.
* Donation of blood or blood products in excess of 500 mL within 12 weeks prior to Screening Visit and/or unwilling to refrain from blood donation for the duration of the study.
* Participant has received an investigational agent within 3 months of the Screening Visit.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes